Table 2.

Joint effects survival analysis between clinical indicators and risk score in STAD OS

Group	Risk Score	Variables	Events/total(n=408)	MST (days)	Crude HR (95% CI)	Crude P	Adjusted HR (95% CI)	Adjusted P£
		Age(years) ₤
A	Low risk	≤60	11/61	NA	1		1
B	Low risk	>60	39/138	1747	1.620(0.829-3.166)	0.158	2.207(1.057-4.608)	0.035
C	Low risk	≤60	32/63	782	3.153(1.588-6.258)	0.001	3.623(1.714-7.661)	0.001
D	High risk	>60	81/140	526	4.591(2.435-8.656)	<0.0001	6.296(3.129-12.670)	<0.0001
		Gender
a	Low risk	Female	10/63	NA	1		1
b	Low risk	Male	40/141	2197	1.910(0.954-3.822)	0.068	2.338(1.087-5.027)	0.030
c	High risk	Female	45/80	533	4.868(2.452-9.666)	<0.0001	6.375(2.981-13.632)	<0.0001
d	High risk	Male	69/124	552	4.790(2.465-9.310)	<0.0001	5.418(2.590-11.334)	<0.0001
		Tumor Stage&
1	Low risk	Stage I	5/34	2197	1		1
2	Low risk	Stage II	11/61	NA	1.433(0.497-4.133)	0.506	1.433(0.497-4.133)	0.506
3	Low risk	Stage III	21/83	1747	1.958(0.738-5.199)	0.177	1.958(0.738-5.199)	0.177
4	Low risk	Stage IV	9/20	570	4.547(1.522-13.584)	0.007	4.547(1.522-13.584)	0.007
5	High risk	Stage I	7/18	1811	3.145(0.997-9.920)	0.051	3.145(0.997-9.920)	0.051
6	High risk	Stage II	24/65	1043	3.642(1.384-9.586)	0.009	3.642(1.384-9.586)	0.009
7	High risk	Stage III	61/91	439	7.236(2.895-18.087)	<0.0001	7.236(2.895-18.087)	<0.0001
8	High risk	Stage IV	15/19	274	9.660(3.505-26.622)	<0.0001	9.660(3.505-26.622)	<0.0001
		Tumor Stage&
I	Low risk	Stage I+II	16/95	NA	1		1
II	Low risk	Stage III+IV	30/103	1747	1.873(1.020-3.4360	0.043	3.154(1.380-7.212)	0.006
III	High risk	Stage I+II	31/83	1095	2.793(1.525-5.116)	0.001	2.701(1.466-4.974)	0.001
IV	High risk	Stage III+IV	76/110	401	6.049(3.517-10.406)	<0.0001	10.172(4.657-22.216)	<0.0001

Notes: £Adjusted for tumor stage. ₤ Age information are unavailable in 6 patients; & Tumor stage information are unavailable in 17 patients. OS, overall survival; STAD, colon adenocarcinoma; MST, median survival time; HR, hazard ratio; CI, confidence interval.